Protection of Radiotherapy‐Induced Xerostomia with Vitamin E+C Complex

Abstract

POSTERSobjective of this study is to 1) describe a novel HPV-positive LSCC cell line and 2) report the prevalence of HPV-positive LSCC in a select patient population.Method: Culture of an HPV-positive LSCC primary tumor and derived cell-line determined by p16 immunohistochemical (IHC) staining, HPV in-situ hybridization (ISH), and HPV PCRMassArray using E6-type-specific primers. Retrospective analysis of the HPV-status in 123 LSCC tissue micro array (TMA) patient specimens from 1985-2000 as determined by p16-IHC and HPV-ISH staining.Results: A 51-year-old man with no tobacco or alcohol history was diagnosed with a T4N0M0 of the true vocal cord. Tumor location was confirmed by laryngoscopy and CT-imaging. After total laryngectomy the tumor was cultured into a cell line (UM-SCC-105). The primary tumor specimen and LSCC derived UM-SCC-105 are HPV-positive and contain HPV-18 as established by p16 IHC, HPV-ISH and PCR-MassArray. In the TMA cohort, 19% (23/123) of tumors were positive for p16, and 3 were positive for HPV-ISH. Based on p16 and ISH results, 2.4% (3/123) of tumor samples were determined to be HPV-positive. Conclusion:In this cohort, prevalence of HPV in LSCC was 2.4%. Given the HPV-induced HNSCC cancer epidemic, greater understanding for HPV in LSCC is warranted. UM-SCC-105 is the first HPV-18 positive LSCC cell line described, and it will aid in future research to better understand the pathogenesis of HPV in LSCC. 2) Present the statistics on the MTNS and why we feel this is a great adjunct in the management of thyroid nodules. 3) Describe a new tool at the clinician's disposal that will help better manage patients with thyroid nodules. Head and Neck SurgeryMethod: This is a prospective study. A total of 245 consecutive patients were enrolled between July 2009 and March 2011. McGill Thyroid Nodule Score (MTNS), age, gender, and extent of surgery were recorded preoperatively. Final pathology was recorded postthyroidectomy. The percentage of malignancy was calculated for each MTNS score. Using Fisher exact test, the risk of malignancy for each group was compared to that anticipated based on the MTNS. We then used linear regression to plot a best fit curve for both the retrospective and prospective data and compared the 2.Results: We found no statistically significant difference when comparing the risk of malignancy between the retrospective group originally used to create the MTNS and the prospective group used to validate this tool with P > .05 for all groups. Regression analysis revealed linear curves and also showed no significant difference between both groups (P = .35). Conclusion:The MTNS system has been validated prospectively and is a unified and individualized tool to help clinicians with multiple aspects in the management of patients with thyroid nodules. This includes discussion with patients regarding the risk of their nodules harbouring malignancy, decisions regarding extent of surgery, and discussion between physicians.